5XUJ
Crystal structure of PDE10A in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine
Summary for 5XUJ
| Entry DOI | 10.2210/pdb5xuj/pdb |
| Descriptor | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, ZINC ION, MAGNESIUM ION, ... (5 entities in total) |
| Functional Keywords | pde10a inhibitor, hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
| Biological source | Homo sapiens (Human) |
| Cellular location | Cytoplasm: Q9Y233 |
| Total number of polymer chains | 2 |
| Total formula weight | 79635.98 |
| Authors | Amano, Y.,Honbou, K. (deposition date: 2017-06-23, release date: 2018-03-14, Last modification date: 2024-03-27) |
| Primary citation | Chino, A.,Seo, R.,Amano, Y.,Namatame, I.,Hamaguchi, W.,Honbou, K.,Mihara, T.,Yamazaki, M.,Tomishima, M.,Masuda, N. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors. Chem. Pharm. Bull., 66:286-294, 2018 Cited by PubMed Abstract: In this study, we report the identification of potent pyrimidoindazoles as phosphodiesterase10A (PDE10A) inhibitors by using the method of fragment-based drug discovery (FBDD). The pyrazolopyridine derivative 2 was found to be a fragment hit compound which could occupy a part of the binding site of PDE10A enzyme by using the method of the X-ray co-crystal structure analysis. On the basis of the crystal structure of compound 2 and PDE10A protein, a number of compounds were synthesized and evaluated, by means of structure-activity relationship (SAR) studies, which culminated in the discovery of a novel pyrimidoindazole derivative 13 having good physicochemical properties. PubMed: 29491261DOI: 10.1248/cpb.c17-00836 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.44 Å) |
Structure validation
Download full validation report






